Table 2.
Treatment-related adverse events occurring in ≥10% of patients
| Adverse event | All grades a | Apatinib (n = 25), n (%) | ||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | ||
| Fatigue | 22 (88) | 13 (52) | 7 (28) | 2 (8) |
| Hand-foot syndrome | 20 (80) | 5 (20) | 10 (40) | 5 (20) |
| AST increased | 17 (68) | 16 (64) | 1 (4) | |
| Proteinuria | 16 (64) | 7 (28) | 6 (24) | 3 (12) |
| Thrombocytopenia | 16 (64) | 13 (52) | 3 (12) | |
| Diarrhea | 16 (64) | 9 (36) | 7 (28) | |
| Headache | 15 (60) | 13 (52) | 2 (8) | |
| Nausea | 14 (56) | 10 (40) | 3 (12) | 1 (4) |
| Decreased appetite | 14 (56) | 11 (44) | 3 (12) | |
| Dizziness | 14 (56) | 13 (52) | 1 (4) | |
| Hypertension | 13 (52) | 5 (20) | 8 (32) | |
| Urine occult blood | 12 (48) | 11 (44) | 1 (4) | |
| Anemia | 12 (48) | 7 (28) | 5 (20) | |
| ALT increased | 11 (44) | 9 (36) | 2 (8) | |
| Mucositis oral | 10 (40) | 5 (20) | 4 (16) | 1 (4) |
| WBC decreased | 10 (40) | 6 (24) | 4 (16) | |
| Blood bilirubin increased | 10 (40) | 7 (28) | 3 (12) | |
| Hyponatremia | 10 (40) | 10 (40) | ||
| Vomiting | 10 (40) | 7 (28) | 2 (8) | 1 (4) |
| Neutrophilic granuloaytopenia | 9 (36) | 5 (20) | 3 (12) | 1 (4) |
| Cough | 8 (32) | 8 (32) | ||
| Creatinine increased | 7 (28) | 5 (20) | 2 (8) | |
| Hypochloremia | 5 (20) | 5 (20) | ||
| Lymphocytopenia | 5 (20) | 1 (4) | 1 (4) | 3 (12) |
| Weight loss | 5 (20) | 5 (20) | ||
| Chest distress | 5 (20) | 4 (16) | 1 (4) | |
| Hoarseness | 4 (16) | 4 (16) | ||
| Hypertriglyceridemia | 4 (16) | 4 (16) | ||
| GGT increased | 3 (12) | 2 (8) | 1 (4) | |
| Constipation | 3 (12) | 3 (12) | ||
aNo grade 4 or 5 adverse events occurred
ALT alanine transaminase, AST aspartate transferase, GGT gamma-glutamyltransferase, WBC white blood cell count